Holle L H, Humke U, Trampert L, Ziegler M, Kirsch C M, Oberhausen E
Abteilung für Nuklearmedizin der Radiologischen Klinik, Universitätskliniken des Saarlandes, Homburg/Saar.
Urologe A. 1997 Nov;36(6):540-7. doi: 10.1007/s001200050134.
Systemic administration of strontium-89 is an important option for pain relief in advanced prostate carcinoma with multiple osseous metastases. Recently, rhenium-186-HEDP was introduced as a new substance which has important advantages (shorter physical half-life, scintigraphic imaging, dose distribution). The myelosuppressive effect can be estimated more accurately in advance, so that adverse effects can be reduced and the treatment can be repeated after a shorter period of time and more often. Our study comprises 15 treatments with rhenium-186-HEDP in advanced prostate cancer patients using the 1.4- to 2-fold standard dose. The response rate, estimated as reduction in pain and increase in patient mobility, was 87% with no major myelosuppressive effects. The mean duration of pain relief was 4-6 weeks. All four patients with repeated therapy were also responding to the second treatment. Radionuclide therapy for painful osseous metastases with rhenium-186-HEDP appears to be an effective and, even at higher doses, safe procedure.
对于伴有多处骨转移的晚期前列腺癌患者，全身给予锶-89是缓解疼痛的重要选择。最近，铼-186-羟基亚乙基二膦酸盐（rhenium-186-HEDP）作为一种具有重要优势（物理半衰期较短、可进行闪烁显像、剂量分布）的新物质被引入。骨髓抑制作用可提前更准确地评估，从而减少不良反应，并且治疗可在更短时间内更频繁地重复进行。我们的研究包括对15例晚期前列腺癌患者使用1.4至2倍标准剂量的铼-186-羟基亚乙基二膦酸盐进行治疗。以疼痛减轻和患者活动能力增强来评估，缓解率为87%，且无严重骨髓抑制作用。疼痛缓解的平均持续时间为4至6周。所有4例接受重复治疗的患者对第二次治疗也有反应。用铼-186-羟基亚乙基二膦酸盐对疼痛性骨转移进行放射性核素治疗似乎是一种有效的方法，即使在较高剂量下也是安全的。
